Circio strengthens its focus on next generation circular RNA therapeutics with additional cost reductions
· Closing of Finnish subsidiary · The Board of Directors will be reduced from seven to four persons · The management team will be restructured to five persons · Cost savings will extend the runway on existing resourcesEarlier this year, Circio announced a strategic shift to prioritize and accelerate its innovative and differentiated circVec circular RNA platform. To establish a strong foundation for building a novel pre-clinical pipeline, the company's activities and organization have been further optimized to support and reinforce circVec development in rare disease and vaccines.